Large gap with delayed quotes
|
Last quote
12/27/2024 -
20:00:00
|
Bid
12/27/2024 -
15:59:59
|
Bid Volume |
Ask
12/27/2024 -
15:59:59
|
Ask Volume |
|---|---|---|---|---|
|
121.50
-1.87
(
-1.52% )
|
121.50
|
1,900 |
121.66
|
600 |
Analysis date: 24.12.2024
Global Evaluation
Slightly positive
Slightly positive
The stock is classified in the slightly positive zone since 29.10.2024.
Interest
Weak
Weak
Weak interest since 20.12.2024.
Earnings Rev Trend
Negative
Negative
Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 09.08.2024 at a price of 125.34.
Evaluation
Undervalued
Undervalued
Based on its growth potential and our own criteria, at its current price the stock is moderately undervalued.
MT Tech Trend
Negative
Negative
The forty day Medium Term Technical Trend is negative since 20.12.2024. The confirmed Technical Reverse point (Tech Reverse + 1.75%) is
4wk Rel Perf
5.44%
5.44%
The four week relative overperformance versus SP500 is 5.44%.
Sensibility
Low
Low
The stock has been on the low-sensitivity level since 29.10.2024.
Bear Market Factor
Low
Low
On average, the stock has a tendency to minimize the drops in the index by -1.06%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 3.78%.
Mkt Cap in $bn
11.53
11.53
With a market capitalization >$8bn, SAREPTA THERAPEUTICS is considered a large-cap stock.
G/PE Ratio
12.68
12.68
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 1.6 often suggests the projected growth is a result of a base effect, meaning the company can often be in a turn around situation. In this case, the estimated PE is a better indicator of a stock's expected growth than the Long Term Growth (LT Growth).
LT P/E
8.78
8.78
The estimated PE is for the year 2026.
LT Growth
111.41%
111.41%
The annualized growth estimate is for the current year to 2026.
Avg. Nb analysts
14
14
Over the last seven weeks, an average of 14 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
79
79
For 1% of index variation, the stock varies on average by 0.79%.
Correlation
0.15
0.15
Stock movements are totally independent of index variations.
Value at Risk
14.63
14.63
The value at risk is estimated at USD 14.63. The risk is therefore 12.00%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
21.05.2013
21.05.2013